Welcome to our dedicated page for BioNTech news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include booster doses for individuals aged 12 and older. The booster maintains the same 30-µg dosage as the primary series, addressing rising COVID-19 cases. Additionally, the waiting time for the booster after primary series completion has been reduced from six to five months. A third primary series dose is also authorized for immunocompromised children aged 5-11. Pfizer and BioNTech have delivered 1 billion doses to low- and middle-income countries, with an additional billion expected in 2022.
BioNTech SE (Nasdaq: BNTX) announced that CEO and Co-founder Ugur Sahin will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 am ET. A live webcast of the presentation will be accessible on the Company’s website, with a replay available for 30 days post-conference.
BioNTech is a leading biopharmaceutical company specializing in innovative immunotherapies for cancer and other serious diseases. It develops mRNA vaccines and collaborates with major pharmaceutical partners, advancing its oncology pipeline and infectious disease therapies.
Pfizer and BioNTech announced an agreement with the European Commission to deliver over 200 million additional doses of their COVID-19 vaccine, COMIRNATY, in 2022. This brings the total planned doses for the year to more than 650 million. The contract will include potential vaccines adapted for the Omicron variant at no additional cost. Pfizer and BioNTech had previously agreed to supply 900 million doses to the EC for 2022 and 2023, with an option for up to an additional 900 million doses.
On December 9, 2021, Pfizer and BioNTech announced the FDA's Emergency Use Authorization (EUA) expansion for a COVID-19 vaccine booster for individuals aged 16 and older. The booster, administered at least six months after the primary series, boasts the same formulation and dosage strength as the initial doses. Phase 3 trial data showed a 95% relative vaccine efficacy after the booster. This authorization, significant amid the emergence of variants like Omicron, reinforces the companies' commitment to global vaccination efforts as they prepare a supplemental Biologics License Application.
The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine booster, now available for individuals aged 16 and older. Administered at least six months post-primary series, the booster has shown a 95% efficacy in combating symptomatic COVID-19 compared to non-booster recipients. Pfizer and BioNTech plan to submit a supplemental Biologics License Application to formalize this authorization. The companies will continue supplying vaccines under existing agreements with the U.S. government through April 2022.
BioNTech SE (Nasdaq: BNTX) has scheduled a digital press conference for December 8, 2021, at 3:00 PM CET to discuss initial laboratory study results regarding the impact of the Omicron variant on COVID-19 vaccine-induced immune responses. The conference will be conducted in English and streamed online, with no on-site attendance for journalists. Recordings and presentations will be available later on their website.
BioNTech is known for its development of mRNA-based therapies for cancer and infectious diseases, collaborating with various global pharmaceutical partners.
Recent preliminary laboratory studies have shown that three doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) effectively neutralize the Omicron variant, while two doses result in a significant reduction in neutralization titers. A third dose increases neutralizing antibodies by 25-fold, achieving comparable levels to those against the wild-type virus. The companies are also advancing a variant-specific vaccine for Omicron, expected to be ready by March 2022, without affecting their projected capacity of four billion doses for the year.
Pfizer and BioNTech announced that three doses of their COVID-19 vaccine effectively neutralize the Omicron variant, while two doses show significantly reduced effectiveness. A booster dose increases neutralizing antibody titers by 25-fold against Omicron, similar to the response against the wild-type virus. Despite two doses providing some protection against severe disease, a third dose is recommended for optimal protection. The companies are developing a variant-specific vaccine for Omicron, expected by March 2022, without impacting their production capacity of four billion doses in 2022.
BioNTech (Nasdaq: BNTX) and Pfizer announced a positive opinion from the European Medicines Agency's CHMP, recommending the use of their COVID-19 vaccine, COMIRNATY, for children aged 5 to under 12. This marks a significant step as it could be the first vaccine authorized in the EU for this age group. The recommendation is based on a Phase 2/3 trial involving approximately 4,500 children, showing a 90.7% efficacy rate in those without prior infection. A final decision from the European Commission is expected soon, impacting all EU member states.
The Pfizer-BioNTech COVID-19 vaccine has shown a remarkable 100% efficacy against COVID-19 in a longer-term analysis involving adolescents aged 12 to 15. The pivotal Phase 3 trial data indicated no serious safety concerns, reinforcing confidence in the vaccine's effectiveness and safety profile. The companies plan to utilize these findings to support full regulatory approval in the U.S. and globally, moving towards a supplemental Biologics License Application to expand approval for this age group. This analysis contributes substantially to the existing data supporting the continued use of the vaccine.